scholarly article | Q13442814 |
P50 | author | Heather E Wheeler | Q30362172 |
Stephen P Hunger | Q64215088 | ||
Ching-Hon Pui | Q66385450 | ||
Naomi Winick | Q91287117 | ||
Meenakshi Devidas | Q102141953 | ||
P2093 | author name string | Claudia Wing | |
Masaaki Komatsu | |||
M Eileen Dolan | |||
Mary V Relling | |||
Shannon M Delaney | |||
Jie J Zheng | |||
William E Evans | |||
Cheng Cheng | |||
Wenjian Yang | |||
Yiping Fan | |||
Mignon L Loh | |||
William L Carroll | |||
Deqing Pei | |||
Xiaomin Lu | |||
Kristine R Crews | |||
Steven W Paugh | |||
Ju Bao | |||
Glen Lew | |||
Barthelemy Diouf | |||
Joseph Robert McCorkle | |||
P2860 | cites work | MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes | Q24635938 |
Treating childhood acute lymphoblastic leukemia without cranial irradiation | Q24644599 | ||
Microtubules as a target for anticancer drugs | Q28253993 | ||
Clinical and electrophysiological studies in vincristine induced neuropathy | Q28373272 | ||
Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia | Q34486506 | ||
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics | Q34551578 | ||
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia | Q35015010 | ||
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment | Q35193958 | ||
Ancestry and pharmacogenetics of antileukemic drug toxicity | Q35828717 | ||
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach | Q35946327 | ||
Treatment of acute lymphoblastic leukemia | Q36366185 | ||
Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations | Q36598611 | ||
Clinical ascertainment of health outcomes among adults treated for childhood cancer | Q37165621 | ||
Pharmacogenomics of serious adverse drug reactions in pediatric oncology. | Q37861998 | ||
Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia | Q40635772 | ||
Vinorelbine induces apoptosis and caspase-3 (CPP32) expression in leukemia and lymphoma cells: a comparison with vincristine | Q40844915 | ||
The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies | Q42231739 | ||
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital | Q44976795 | ||
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment | Q45007602 | ||
CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia | Q47778081 | ||
Vincristine pharmacokinetics after repetitive dosing in children. | Q52206734 | ||
Acute and long-term neurologic complications in children with acute lymphoblastic leukemia. | Q53630764 | ||
Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. | Q54701330 | ||
Acute lymphoblastic leukemia | Q77153499 | ||
Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients | Q80214224 | ||
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | leukemia | Q29496 |
peripheral neuropathy | Q945238 | ||
lymphoblastic leukemia | Q18553852 | ||
P304 | page(s) | 815-823 | |
P577 | publication date | 2015-02-01 | |
P1433 | published in | The Journal of the American Medical Association | Q1470970 |
P1476 | title | Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia | |
P478 | volume | 313 |
Q96431587 | A Metabolomics Approach for Early Prediction of Vincristine-Induced Peripheral Neuropathy |
Q100407536 | A Nuclear Long Non-Coding RNA LINC00618 Accelerates Ferroptosis in a Manner Dependent upon Apoptosis |
Q64109892 | A PRPH splice-donor variant associates with reduced sural nerve amplitude and risk of peripheral neuropathy |
Q41367937 | A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma. |
Q38948499 | Advances and challenges in hereditary cancer pharmacogenetics |
Q39459190 | Advances in adult acute lymphoblastic leukemia therapy |
Q39401025 | An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia |
Q53128895 | Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. |
Q53200053 | Application of stem cell derived neuronal cells to evaluate neurotoxic chemotherapy. |
Q92865754 | Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review |
Q46455283 | CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer |
Q26782604 | Cancer-treatment-induced neurotoxicity--focus on newer treatments |
Q92353408 | Changes in Ecophysiology, Osmolytes, and Secondary Metabolites of the Medicinal Plants of Mentha piperita and Catharanthus roseus Subjected to Drought and Heat Stress |
Q28818565 | Chemotherapy-induced neuropathies-a growing problem for patients and health care providers |
Q39293928 | Chemotherapy-induced peripheral neuropathy: A current review |
Q36421901 | Chemotherapy-induced peripheral neuropathy: Current status and progress |
Q26740689 | Chemotherapy-induced peripheral neuropathy: an update on the current understanding |
Q58778223 | Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients |
Q38664595 | Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics |
Q28087637 | Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration |
Q47979421 | Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial |
Q38864711 | Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus |
Q98891744 | Determination of NUDT15 variants by targeted sequencing can identify compound heterozygosity in pediatric acute lymphoblastic leukemia patients |
Q38589233 | Evaluation of inter-batch differences in stem-cell derived neurons. |
Q46160844 | Future cancer research priorities in the USA: a Lancet Oncology Commission |
Q90156977 | Genetic Variants Associated With Vincristine-Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia |
Q33774499 | Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia |
Q39262358 | Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality |
Q89982350 | Genomic variants of cytarabine sensitivity associated with treatment related mortality in pediatric AML: A report from the Children's Oncology Group |
Q91249010 | Global efforts toward the cure of childhood acute lymphoblastic leukaemia |
Q38796874 | Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer. |
Q80019346 | Induced pluripotent stem cells for therapy personalization in pediatric patients: Focus on drug-induced adverse events |
Q35784497 | Inherited genetic variation in childhood acute lymphoblastic leukemia |
Q37662576 | Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. |
Q99241249 | Management of CNS toxicity of chemotherapy and targeted agents: 2020 |
Q64062172 | Mechanisms of Chemotherapy-Induced Peripheral Neuropathy |
Q47177557 | Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia. |
Q48946163 | Neuroprotective Effect of Matrine in Mouse Model of Vincristine-Induced Neuropathic Pain |
Q49201897 | New model of vincristine-induced neuropathic pain in children: a first step towards prediction and prevention |
Q33557148 | Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. |
Q64269386 | Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity |
Q91634793 | Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management |
Q89453427 | Outcomes after late bone marrow and very early central nervous system relapse of childhood B-Acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433 |
Q33744706 | Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. |
Q36176588 | Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia |
Q91589110 | Peripheral neuropathy in children and adolescents treated for cancer |
Q36117686 | Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy |
Q39796533 | Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy |
Q38419534 | Pharmacogenetic Markers of Drug Efficacy and Toxicity |
Q38895172 | Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia |
Q48264298 | Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia. |
Q64077129 | Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment |
Q28068930 | Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use |
Q38688039 | Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations |
Q64898627 | Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes. |
Q57074608 | Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy: Progress Continues |
Q52686427 | Polyneuropathies. |
Q47599462 | Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice. |
Q50200720 | Questions on asparaginase-associated pancreatitis |
Q47552411 | Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy |
Q64922475 | Severe Neuropathic Pain With Concomitant Administration of Vincristine and Posaconazole. |
Q40605146 | Short-term recovery of chemotherapy-induced peripheral neuropathy after treatment for pediatric non-CNS cancer |
Q90463690 | Somatic and germline genomics in paediatric acute lymphoblastic leukaemia |
Q48331843 | Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients. |
Q38739253 | The role of germline variants in chemotherapy outcome in brain tumors: a systematic review of pharmacogenetic studies. |
Q38728572 | Update on Chemotherapy-Induced Peripheral Neuropathy |
Q91361701 | Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia |
Q47310338 | Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. |
Q88715577 | Vincristine-associated Neuropathy With Antifungal Usage: A Kaiser Northern California Experience |
Q38721382 | Vincristine-induced neuropathy in pediatric patients with acute lymphoblastic leukemia in Oman: Frequent autonomic and more severe cranial nerve involvement. |
Q28078232 | Vincristine-induced peripheral neuropathy in pediatric cancer patients |
Q86478393 | [The second generation sequencing technology and its application in the field of hematologic malignancies] |
Search more.